

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

CIN: L24232MH2007PLC169354;

Tel: +91-22-2498 1650; Fax: +91-22-2497 0127

E-mail: info@rpglifesciences.com; Web: www.rpglifesciences.com



PART I							(Rs. in lakhs)
STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 TH SEPTEMBER, 2015							
PARTICULARS	3 months ended	3 months ended	3 months ended	6 months ended	6 months ended	Year ended	
	30.9.2015	30.6.2015	30.9.2014	30.9.2015	30.9.2014	31.03.2015	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
1. Income from Operations							
(a) Net Sales/Income from Operations (Net of Excise Duty)	6,720	6,650	5,662	13,370	11,541	23,308	
(b) Other Operating Income	121	94	98	215	177	919	
Total Income from Operations (Net)	6,841	6,744	5,760	13,585	11,718	24,227	
2. Expenses							
(a) Cost of Materials Consumed	1,794	1,311	1,743	3,105	3,269	5,920	
(b) Purchases of Stock-in-Trade	882	777	759	1,659	1,275	2,378	
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(432)	290	(361)	(142)	(128)	171	
(d) Employee Benefits Expense	1,797	1,777	1,892	3,574	3,453	6,866	
(e) Depreciation and Amortisation Expense	262	255	300	517	526	1,136	
(f) Provision for Doubtful Debts and Advances (Net)	(20)	16	9	(4)	18	(323)	
(g) Other Expenses	2,272	2,038	2,121	4,310	3,886	7,798	
Total Expenses	6,555	6,464	6,463	13,019	12,299	23,946	
3. Profit/(Loss) from Operations before Other Income, Finance Costs and Exceptional Items	286	280	(703)	566	(581)	281	
4. Other Income	45	28	26	73	56	91	
5. Profit/(Loss) from Ordinary Activities before Finance Costs	331	308	(677)	639	(525)	372	
6. Finance Costs	75	94	70	169	112	272	
7. Profit/(Loss) from Ordinary Activities before Tax	256	214	(747)	470	(637)	100	
8. Tax Expense/(Credit) (including Deferred Tax)	-	-	(8)	-	(14)	-	
9. Net Profit/(Loss) for the period	256	214	(739)	470	(623)	100	
10. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323	
11. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						11,193	
12. Earnings/(Loss) per Share (of Rs. 8 each) (not annualised):							
(a) Basic	1.55	1.29	(4.47)	2.84	(3.77)	0.60	
(b) Diluted	1.55	1.29	(4.47)	2.84	(3.77)	0.60	

PART II						
SELECT INFORMATION FOR THE QUARTER AND HALF YEAR ENDED 30 TH SEPTEMBER, 2015						
PARTICULARS	3 months ended	3 months ended	3 months ended	6 months ended	6 months ended	Year ended
	30.9.2015	30.6.2015	30.9.2014	30.9.2015	30.9.2014	31.03.2015
A PARTICULARS OF SHAREHOLDING						
1. Public Shareholding						
- Number of Shares	5,492,188	5,492,188	6,312,564	5,492,188	6,312,564	5,591,135
- Percentage of Shareholding	33.21	33.21	38.17	33.21	38.17	33.81
2. Promoters and Promoter Group Shareholding						
(a) Pledged/Encumbered						
- Number of Shares	-	-	-	-	-	-
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	-	-	-	-	-	-
- Percentage of Shares (as a % of the total Share Capital of the company)	-	-	-	-	-	-
(b) Non-Encumbered						
- Number of Shares	11,043,917	11,043,917	10,223,541	11,043,917	10,223,541	10,944,970
- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
- Percentage of Shares (as a % of the total Share Capital of the company)	66.79	66.79	61.83	66.79	61.83	66.19

PARTICULARS	3 months ended 30.9.2015
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	2
Disposed of during the quarter	2
Remaining unresolved during the quarter	-

Notes:

1. Standalone Statement of Assets and Liabilities

(Rs. in lakhs)

PARTICULARS	As at 30.9.2015	As at 31.3.2015
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	11,663	11,193
Sub-total - Shareholders' Funds	12,986	12,516
2. Non-Current Liabilities		
(a) Long-term Borrowings	32	32
(b) Deferred Tax Liabilities (Net)	-	-
(c) Other Long-term Liabilities	263	266
(d) Long-term Provisions	158	158
Sub-total - Non-Current Liabilities	453	456
3. Current Liabilities		
(a) Short-term Borrowings	2,934	3,246
(b) Trade Payables	3,816	2,530
(c) Other Current Liabilities	685	664
(d) Short-term Provisions	118	279
Sub-total - Current Liabilities	7,553	6,719
TOTAL - EQUITY AND LIABILITIES	20,992	19,691
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets	10,900	10,524
(b) Long-term Loans and Advances	548	557
Sub-total - Non-Current Assets	11,448	11,081
2. Current Assets		
(a) Inventories	3,871	3,448
(b) Trade Receivables	4,538	4,061
(c) Cash and Bank Balances	89	72
(d) Short-term Loans and Advances	1,046	1,029
Sub-total - Current Assets	9,544	8,610
TOTAL - ASSETS	20,992	19,691

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 29th October, 2015.

3. The results for the quarter ended 30th September, 2015 have been subjected to limited review by the statutory auditors of the Company.

4. The Company is exclusively engaged in the pharmaceuticals segment.

5. Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited

CT. Renganathan

Managing Director

Mumbai, 29th October, 2015